Results from the recent ZENYATTA study indicate that astegolimab, a human IgG2 mAb which targets IL-33 receptor, ST2, reduces asthma exacerbation rates in both eosinophil-high and -low patients with inadequately controlled, severe asthma (165). The gene discussed is IL1RL1; the disease is asthma.